Amgen (AMGN) Stock Drops After Kissei's Tavneos Liver Risk Warning
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowAmgen (AMGN) experienced a decline in its stock price following a warning from Kissei Pharmaceutical regarding liver risks associated with Tavneos. Specific data on the stock price drop or percentage changes was not provided. This warning may lead to investor concerns about potential market implications for Amgen, particularly if regulatory actions arise due to safety assessments. Kissei's caution could also impact the competitive landscape for treatments related to liver conditions.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Amgen Inc. (AMGN)
Amgen is one of the world’s largest biotechnology companies.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier AMGN news
- Amgen (AMGN) Reports 24% Growth Driven by Key Factors
- Amgen (AMGN) Q1 2026 Earnings Beat EPS Forecast
- Novartis (NVS) drug trials target Lp(a) for heart disease prevention
- Zai Lab (ZLAB) and Amgen (AMGN) Collaborate on Lung Cancer Therapy
- Comparative Analysis: Novo Nordisk vs. Amgen in the Weight Loss Market
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Aeromexico Plans New US Flights After Washington Lifts Restrictions
Oct 19
SpaceX AI Computing Power Rental Driving Revenue Growth but Raising Costs
Oct 19
A&W (TSX:AW) Q3 Results Show Margin Squeeze Impact
Oct 18
Aurum PropTech Focuses on Profits and Scale at Earnings Call
Oct 18